Dmitry Balyasny’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Dmitry Balyasny’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-30,800	Closed	-$345K	–	2525
2017 Q3	$345K	Buy	+30,800	New	+$340K	﹤0.01%	1477
2017 Q2	–	Sell	-17,575	Closed	-$172K	–	1935
2017 Q1	$172K	Sell	17,575 -1,130	-6%	-$11.3K	﹤0.01%	1495
2016 Q4	$202K	Buy	18,705 +2,630	+16%	+$26.3K	﹤0.01%	1285
2016 Q3	$165K	Buy	16,075 +4,900	+44%	+$53.4K	﹤0.01%	894
2016 Q2	$146K	Sell	11,175 -5,210	-32%	-$68.3K	﹤0.01%	1070
2016 Q1	$180K	Buy	+16,385	New	+$146K	﹤0.01%	1144

Dmitry Balyasny's SCLN Position: Q4 2017 in Review

Dmitry Balyasny sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 30,800 shares — an estimated $345K sold.

Dmitry Balyasny first reported a position in SCLN in Q1 2016 and held it in 6 quarters. The position peaked at $345K in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

Dmitry Balyasny reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
Dmitry Balyasny sold 30,800 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $345K.
Dmitry Balyasny first reported a position in Sciclone Pharmaceuticals Inc in Q1 2016 and held it in 6 quarters.
Dmitry Balyasny's Sciclone Pharmaceuticals Inc position peaked at $345K in Q3 2017.
0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Balyasny Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.